Navigation Links
Pharmaceutical Executive Magazine's 2013 Drug "Brand of the Year" Awarded to Leading Merck Diabetes Drug Januvia
Date:3/26/2013

NEW YORK, March 26, 2013 /PRNewswire/ -- Pharmaceutical Executive, the monthly magazine and daily online publication of record on analytics, trends and personalities in the biopharmaceutical industry worldwide, announced today the choice for its 2013's drug Brand of the Year: Merck's Januvia [sitagliptin], a first in class dipeptide peptidase-4 inhibitor treatment for adult onset [Type II] diabetes.    

Brand of the Year is an independent, non-promotional designation, selected annually since 1998 by the publication's editorial staff and expert Advisory Board. It seeks to recognize FDA-authorized prescription medicines with a track record of clinical innovation as well as consistent, real-world performance and appeal to patients. It must also demonstrate novelty in the developer's approach to brand-building and market awareness activities.

Januvia was developed and has been marketed by Merck since 2006, and, along with its sister drug Janumet, is now the biggest-selling therapeutic franchise in the company's 122 year history.  "We are pleased to devote our March cover to this important medicine, not only because of its breakthrough status in regulating blood sugar among Type II patients, with fewer side effects, but also for the higher profile it has given to a debilitating chronic condition that contributed to the deaths of more than 4.6 million people worldwide in 2011," said Pharm Exec Editor-in-Chief William Looney .

The story, authored by Senior Editor Ben Comer , features interviews and backgrounders with several top Merck executives, representatives of the original product launch team, patient groups and independent medical experts, all of whom point to the need for further progress by the pharmaceutical industry in combating persistent challenges in managing this growing illness – despite the success of clinically effective medicines like Januvia, half of all diabetes patients still fail to complete the drug therapy recommended by their physician.  

Full text of the story as well as a video display summary is available on the Pharmaceutical Executive web site, at www.pharmexec.com.  Editorial staff are also available for comment and interviews:  please contact Email.

Pharmaceutical Executive probes the interface of business practice and public policy for the global biopharmaceutical, vaccine and medical device industries.  PharmExec's editorial remit covers strategy in the "c-suite" as well as regulatory and legal actions; sales promotion and marketing; R&D; finance; human resources; pricing and market access; and new technology.  Published by Advanstar Communications, PharmExec's editorial content is available in the award-winning monthly print edition as well as in a number of digital platforms.  

Media Contact: 
William Looney 
212-951-6735

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.


'/>"/>
SOURCE Pharmaceutical Executive
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
8. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
9. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
10. Icahn Issues Statement Regarding Amylin Pharmaceuticals
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... 24, 2016 Research and Markets has ... Companion Diagnostic Tests" report to their offering. ... Diagnostics The World Market for Companion Diagnostics ... diagnostics. Market analysis in the report includes the following: ... Vitro Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Final Cut Pro X users can now reveal the media of their split ...
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution is ... emergency ambulance transport experience for the millions of people who require these medical ... the taxi industry through the use of technology. Now, SmartEMS has put forth ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... , ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a ... fitness app plans to fix the two major problems leading the fitness industry today:, ... type program , They don’t eliminate all the reasons people quit their exercise ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
Breaking Medicine News(10 mins):